Outcome of Preoperative Chemotherapy in Stomach Cancer
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: C169- Malignant neoplasm of stomach, unspecified
- Registration Number
- CTRI/2019/01/016901
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients attending surgery clinics with TNM stage T3, T4, any N, M0 histologically proven adenocarcinoma stomach by UGI endoscopy guided biopsy and Contrast enhanced CT scan(CECT) will be included in the study
Exclusion Criteria
Patients with any other coexisting malignancies, age 70 and above, those who are already on chemotherapy, and patients with recurrence will be not included in the study. Tumors localized to Gastroesophageal junction (Type I) will be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method I.To study the down-staging effect of Neoadjuvant Chemotherapy on tumor size, Tumor Node Metastasis (TNM) stage of Locally Advanced Carcinoma Stomach. <br/ ><br>II.To study R0 resection rates with and without Neoadjuvant Chemotherapy in Locally Advanced Carcinoma Stomach. <br/ ><br>Timepoint: I.After 3 to 4 cycles of Neoadjuvant chemotherapy, response will be assessed with CECT abdomen. <br/ ><br> <br/ ><br>II. R0 resection will be studied on post operative biopsy report. Patient will be taken for surgery after response assessment after 3 to 4 cycles of NACT <br/ ><br>
- Secondary Outcome Measures
Name Time Method To evaluate intraoperative complications and post operative complications with and without Neoadjuvant Chemotherapy in the short term follow up in patients with Locally Advanced Carcinoma Stomach.Timepoint: 3 months